Sanofi NV25 (SANNV.PA) Stock Income Statement
Europe - Euronext Paris - EPA:SANNV - FR001400UEY9 - Common Stock
88.5 EUR
0 (0%)
| TTM (2020-9-30) | 2019 (2019-12-31) | 2018 (2018-12-31) | 2017 (2017-12-31) | 2016 (2016-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 56.89B | 37.63B | 35.68B | 36.22B | 34.70B | |||
| Minority Interest Expense | -55.00M | -31.00M | -104.00M | -121.00M | -91.00M | |||
| Cost Of Goods | 18.18B | 11.98B | 11.44B | 11.61B | 10.70B | |||
| Gross Profit | 38.71B | 25.66B | 24.24B | 24.61B | 24.00B | |||
| Operating Expenses | 26.25B | 18.59B | 17.87B | 17.57B | 16.60B | |||
| Research and Development | 8.40B | 6.01B | 5.89B | 5.47B | 5.16B | |||
| Selling, General, and Administrative Expenses | 14.18B | 9.77B | 9.77B | 10.07B | 9.42B | |||
| Operating Income | 12.47B | 7.07B | 6.37B | 7.04B | 7.39B | |||
| Interest Income/Expense | 7.01B | -210.00M | -273.00M | -221.00M | -237.00M | |||
| Other Income/Expense | N/A | -93.00M | 2.00M | -52.00M | -619.00M | |||
| Non Recurring Items | -3.16B | -3.94B | -1.70B | -1.24B | -860.00M | |||
| Income Before Taxes | 16.22B | 2.82B | 4.41B | 5.53B | 5.67B | |||
| Income Tax | 2.04B | 139.00M | 481.00M | 1.72B | 1.32B | |||
| Net Income | 14.67B | 2.81B | 4.31B | 8.42B | 4.71B | |||
| EBITDA | N/A | 14.52B | 10.65B | 10.73B | 10.69B | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | 11.67 | 2.23 | 3.43 | 6.64 | 3.63 | |||
| Statistics | ||||||||
| Gross Profit Margin | 68.05% | 68.18% | 67.95% | 67.94% | 69.16% | |||
| Profit Margin | 25.79% | 7.46% | 12.07% | 23.24% | 13.57% | |||
| Operating Profit Margin | 21.91% | 18.77% | 17.86% | 19.44% | 21.30% | |||
All data in